Conference Coverage
Latest News
Lecanemab’s Promise and Peril: Alzheimer’s Treatment Dilemma
A study found a minimum clinically important difference for lecanemab treatment in mild disease and possible amyloid-related abnormalities on on...
Latest News
Lower Urinary Tract Symptoms Associated With Poorer Cognition in Older Adults
Data from a large cohort study suggested the need for improved strategies to diagnose and treat urinary symptoms in older adults.
Conference Coverage
High-Potency Cannabis Tied to Impaired Brain Development, Psychosis, Cannabis-Use Disorder
“Clearly new treatment strategies are needed to address the mounting challenge of cannabis-use disorder risk in teens and young adults.”
Latest News
Inappropriate Medication Use Persists in Older Adults With Dementia
Data from a cross-sectional analysis suggested troubling trends in use of medications by older adults.
Conference Coverage
New mRNA Vaccines in Development for Cancer and Infections
Different forms and designations of mRNA vaccines are used, depending on the application and desired effect.
Conference Coverage
For Pediatric LGS, Cenobamate Shows Promise
Small, uncontrolled study shows reductions in hospitalizations and emergency room visits, but limitations make the results difficult to interpret...
Guidelines
Multidisciplinary Team Develops New Guidelines for Sjögren-Related Neuropathy
New evidence-based practice guidelines related to peripheral neuropathy related to Sjögren disease have been developed by a multidisciplinary...
Conference Coverage
Novel Treatment Options for Epilepsy
Three novel therapies for epilepsy, including a first-in-man product, are positive.
Conference Coverage
TMS May Be a Good Alternative to ECT in Depression
A retrospective analysis shows better outcomes for TMS, but better population comparisons may be needed.
Conference Coverage
Major Gaps in Care and Management of Neurologic Diseases
Because many of these diseases are first detected during a visit with a primary care physician, it is important to understand the timeline from...
Conference Coverage
Complement Inhibitor Scores Impressive Data in CIDP
Phase 2 study shows riliprubart performs well in both refractory and treatment-naive patients.